// App-Quantinova.ai

P1-10-17 : cGAS-STING driven immune activation predicts response to neoadjuvant chemotherapy and suggests rational IO combination therapies: Results of the Neo-DDIR study

Researchers

Presenter

  • Stuart A McIntosh

Principal Investigators

  • Kienan I Savage

  • Colin James

  • Tong Lioe

  • Steven Walker

  • Keith Lowry

  • Laura Knight

  • Andrena McGavigan

  • Gemma Logan

  • Jane Hurwitz

  • Stephen J Kirk

  • Paul Harkin

  • Richard D Kennedy

  • Eileen E Parkes

Medical Centers

  • Queen's University Belfast, Belfast, United Kingdom

  • Belfast Health and Social Care Trust, Belfast, United Kingdom

  • Northern Health and Social Care Trust, Antrim, United Kingdom

  • Almac Diagnostics Ltd., Craigavon, United Kingdom

  • Ulster Hospital,Dundonald,United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • erb-b2 receptor tyrosine kinase 2

  • Solute Carrier Family 22 Member 3

  • tumor-infiltrating lymphocytes

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Epirubicin

  • taxane

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved